Subscribe To
Fda advisors consider crispr gene-editing treatment for sickle cell anemia
Nearly all patients treated so far have been relieved of the blood-clogging crises of the disease....
October 31, 2023, 3:43 pm
Bristol myers says it needs another year to hit target for new drugs
Drugmaker Bristol Myers Squibb on Thursday pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as t...
October 26, 2023, 7:02 am
3 gene editing stocks to generate super-charged gains
Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroduc...
October 18, 2023, 11:05 am
Jasper therapeutics to present new positive data on briquilimab conditioning in patients with fanconi anemia at the 2023 fanconi anemia research fund scientific symposium
REDWOOD CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on d...
September 21, 2023, 8:00 am
Gsk's momelotinib gets fda nod for myelofibrosis-related anemia
GSK's Ojjaara (momelotinib) is the first and the only drug approved to treat myelofibrosis patients with anemi...
September 18, 2023, 10:32 am
Incyte shares drop after fda approves gsk's competing blood-cancer treatment
Incyte Corp. INCY, -1.47% shares dropped more than 5% premarket on Monday after the U.S. Food and Drug Administration on Friday approved a GSK PLC GSK...
September 18, 2023, 8:11 am
Us fda approves gsk's anemia treatment
British drugmaker GSK Plc said on Friday the U.S. Food and Drug Administration had approved its experimental drug to treat anemic patients with a type...
September 15, 2023, 4:25 pm
Bristol myers (bmy) gets fda nod for reblozyl label expansion
Bristol Myers' (BMY) Reblozyl is now indicated in the United States as the first-line treatment of anemia ...
August 29, 2023, 10:31 am
Anemia, chronic renal disease and chronic heart failure: the cardiorenal anemia syndrome
The mortality and morbidity of congestive heart failure (CHF) have improved slightly over the years but are still very high. Many patients with CHF ar...
June 15, 2023, 1:46 pm
Precipio’s omnia™ methodology enables diagnosis of mds with peripheral blood instead of bone marrow biopsy
Use of HemeScreen® technology enables diagnosis without the need for painful, invasive sampling NEW HAVEN, Conn., June 14, 2023 (GLOBE NEWSWIRE) — ...
June 14, 2023, 1:49 pm
Lobe sciences appoints baxter phillips iii as chief operating officer
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has appointed Baxter Phillips III to the newly created position of chief operating officer (COO) eff...
June 7, 2023, 8:16 am
Bristol myers squibb to present first results at asco and eha from phase 3 commands study of reblozyl® (luspatercept-aamt) in first-line treatment of anemia in adults with lower-risk myelodysplastic s
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Present First Results at ASCO & EHA from Phase 3 COMMANDS Study of Reblozyl in First-Line Trea...
May 25, 2023, 5:00 pm
Bristol myers squibb to present first results at asco and eha from phase 3 commands study of reblozyl® (luspatercept-aamt) in first-line treatment of anemia in adults with lower-risk myelodysplastic s
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Present First Results at ASCO & EHA from Phase 3 COMMANDS Study of Reblozyl in First-Line Trea...
May 25, 2023, 5:00 pm
Why shares of akebia therapeutics were up tuesday
Akebia gained approval for Vafseo, its anemia therapy for chronic kidney disease patients, in Great Bri...
May 23, 2023, 11:27 am
New study confirms consistent risk of myelosuppression across all patients receiving chemotherapy for small cell lung cancer
Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events RESEARCH TRIANGLE PARK, N.C., May 16, 2023 (GL...
May 16, 2023, 11:30 am
New results from phase 2 trial confirm benefit of trilaciclib in reducing adverse events related to an antibody drug conjugate (adc)
– On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutrope...
May 10, 2023, 11:31 am
The acquired aplastic anemia market is projected to reach usd 10.25 billion by 2030, from usd 7.27 billion in 2022,registering a cagr of 4.20% during the forecast period 2023-2030| data by contrive da
According to a market research study published by Contrive Datum Insights, . The global aplastic anemia ...
May 8, 2023, 5:20 pm
Jasper therapeutics announces positive follow-up clinical data from investigator-sponsored study of briquilimab conditioning in fanconi anemia patients at the 2023 transplantation & cellular therapy m
Both Fanconi anemia patients treated with briquilimab successfully engrafted with neutrophil engraftmen...
February 17, 2023, 1:10 pm
Gsk's daprodustat drug for anemia due to ckd gets fda nod
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease...
February 2, 2023, 6:04 pm
2023 a big year for testosterone: abbvie and ani pharmaceuticals best positioned to benefit
Results from three major testosterone trials expected in 2023, including the largest testosterone cardiovascular safety/efficacy trials for men and wo...
January 1, 2023, 8:29 am
